Abstract
While aspirin and other non-steroid anti-inflammatory drugs (NSAIDs) are associated with gastric mucosal damage, they might reduce the risk for gastric cancer. In a population-based case–control study in 5 Swedish counties, we interviewed 567 incident cases of gastric cancer and 1165 controls about their use of pain relievers. The cases were uniformly classified to subsite (cardia/non-cardia) and histological type and information collected on other known risk factors for gastric cancer. Helicobacter pylori serology was tested in a subset of 542 individuals. Users of aspirin had a moderately reduced risk of gastric cancer compared to never users; odds ratio (OR) adjusted for age, gender and socioeconomic status was 0.7 (95% CI = 0.6–1.0). Gastric cancer risk fell with increasing frequency of aspirin use (P for trend = 0.02). The risk reduction was apparent for both cardia and non-cardia tumours but was uncertain for the diffuse histologic type. No clear association was observed between gastric cancer risk and non-aspirin NSAIDs or other studied pain relievers. Our finding lends support to the hypothesis that use of aspirin reduces the risk for gastric cancer. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ekstrom AM, Eriksson M, Hansson LE, Lindgren A, Signorello LB, Nyren O and Hardell L (1999a) Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res 59: 5932–5937
Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A and Nyren O (1999b) Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 91: 786–790
Ekstrom AM, Serafini M, Nyren O, Hansson LE, Ye W and Wolk A (2000) Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 87: 133–140
Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr and Blot WJ (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97–102
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–1316
Graham DYED and Evans DJ (1994) An accurate, rapid and convenient physician-office serologic test for detection of Helicobacter pylori infection (abstr.). Am J Gastroenterol 89: 1305 (A81)
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311
Hansson LE, Baron J, Nyren O, Bergstrom R, Wolk A, Lindgren A and Adami HO (1994) Early-life risk indicators of gastric cancer. A population-based case-control study in Sweden. Int J Cancer 57: 32–37
Hawkey CJ (1996) Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 220: 124–127
Hosmer DW and Lemeshow S (1989). Applied logistic regression, Wiley: New York
Isomaki HA, Hakulinen T and Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31: 691–696
Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418–1423
Kune GA, Kune S and Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404
Laurén (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64: 31–49
Lupulescu A (1996) Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54: 83–94
Marchildon PA, Ciota LM, Zamaniyan FZ, Peacock JS and Graham DY (1996) Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection. J Clin Microbiol 34: 1147–1152
Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575–5589
Misumi A, Murakami A, Harada K, Baba K and Akagi M (1989) Definition of carcinoma of the gastric cardia. Langenbecks Arch Chir 374: 221–226
Morales TG (1997) Adenocarcinoma of the gastric cardia. Dig Dis 15: 346–356
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD and Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355–358
Rothman KJ (1986). Modern epidemiology, Little Brown: Boston
Sawaoka H, Kawano S, Tsuji S, Tsuji M, Sun W, Gunawan ES and Hori M (1998a) Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 59: 313–316
Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K and Hori M (1998b) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061–G1067
Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H and Hori M (1998c) Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 27: S47–S52
Schreinemachers DM and Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146
Shiff SJ and Rigas B (1997) Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992–1998
Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327
Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, Fusamoto H and Kamada T (1996) Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 55: 179–183
Zaridze D, Borisova E, Maximovitch D and Chkhikvadze V (1999) Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 82: 473–476
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Akre, K., Ekström, A., Signorello, L. et al. Aspirin and risk for gastric cancer: a population-based case–control study in Sweden. Br J Cancer 84, 965–968 (2001). https://doi.org/10.1054/bjoc.2001.1702
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1702
Keywords
This article is cited by
-
DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use
Scientific Reports (2019)
-
Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
BMC Cancer (2018)
-
Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer
American Journal of Gastroenterology (2018)
-
Role of inflammatory gene variants in Helicobacter pylori-related gastric cancer ⁎
Oncology and Translational Medicine (2015)
-
Cyclooxygenase-2 and Gastric Cancer
Cancer and Metastasis Reviews (2011)
